by Lentiviral vectors are advanced gene delivery tools used for gene therapy and experimental research in various medical applications such as cancer, genetic disorders, and infectious diseases. They have the ability to efficiently deliver therapeutic genes to dividing as well as non-dividing cells. The rising prevalence of genetic disorders and cancer coupled with increasing adoption of gene therapy has boosted demand for lentiviral vectors in recent years.
The global lentiviral vectors Market is estimated to be valued at US$ 292 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The growing demand for gene therapy is the major driver propelling growth of the lentiviral vectors market. Gene therapy holds potential to cure many life-threatening genetic diseases by correcting defective genes or introducing new genes inside the body’s cells. Lentiviral vectors have emerged as a viable vector system for delivering therapeutic genes in vivo for various monogenic as well as acquired diseases. Their ability to efficiently integrate therapeutic transgenes into the genomes of both dividing and non-dividing cells has enabled development of gene therapies for several diseases. Growing research in this area is expected to boost adoption of lentiviral vectors in the coming years.
SWOT Analysis
Strength: Lentiviral vectors have high transfection efficiency and ability to integrate into host genome. They can deliver large genetic payloads and provide long-term expression of transgenes.
Weakness: Production of lentiviral vectors is a complex multi-step process requiring specialized equipment and techniques. They also pose risks of random integration and activation of oncogenes.
Opportunity: Growing stem cell research and gene therapy clinical trials are driving demand. Expanding applications in immunotherapy, vaccine development and regenerative medicine offer new opportunities.
Threats: Strict regulations for genetic modified products may slow commercialization. Biosafety issues related to random transgene integration and potential immune responses are challenges.
Key Takeaways
The global Lentiviral Vectors Market Growth is expected to witness high growth. The global lentiviral vectors Market is estimated to be valued at US$ 292 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030.
Regional analysis: North America dominates the market currently due to growing research activities in gene therapy and stem cell research in the US and Canada. Asia Pacific is expected to grow at fastest pace due to increasing government investments in life sciences research in China, India and South Korea.
Key players
Key players operating in the lentiviral vectors market are Thermo Fisher Scientific Inc., Sirion-Biotech GmbH (Revvity), Vector Biolabs, OriGene Technologies, Inc., SignaGen Laboratories, Sino Biological, Inc., Takara Bio Inc., Cell Biolabs, Inc., GenTarget Inc., GENEMEDI, bluebird bio, Inc., Cellomics Technology, LLC., Virica Biotech, Oxford Biomedica, and ANDELYN BIOSCIENCES. Growing commercial demand for lentiviral vectors in drug development and clinical applications is encouraging new market entrants.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
